Electrocore, Inc. (ECOR) — SEC Filings
Electrocore, Inc. (ECOR) — 27 SEC filings. Latest: 144 (Apr 23, 2026). Includes 12 8-K, 6 10-Q, 2 10-K.
View Electrocore, Inc. on SEC EDGAR
Overview
Electrocore, Inc. (ECOR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: electroCore, Inc. reported a net loss of $3.405 million for the three months ended September 30, 2025, an increase from $2.497 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss widened to $10.931 million from $8.658 million in 2024. Despite increasing net
Sentiment Summary
Across 27 filings, the sentiment breakdown is: 2 bearish, 23 neutral, 2 mixed. The dominant filing sentiment for Electrocore, Inc. is neutral.
Filing Type Overview
Electrocore, Inc. (ECOR) has filed 1 144, 6 10-Q, 12 8-K, 1 DEF 14A, 1 8-K/A, 2 10-K, 1 S-1/A, 1 S-1, 1 SC 13D/A, 1 SC 13G/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (27)
Risk Profile
Risk Assessment: Of ECOR's 24 recent filings, 3 were flagged as high-risk, 17 as medium-risk, and 4 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $22.789M |
| Net Income | -$10.931M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $13.2M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. Peter J. McKenna
- Ms. Karen L. King
- Daniel S. Goldberger
- Ira L. Kotel, Esq.
- Dr. Francis R. Smith
- Ms. Jennifer L. Smith
- Theofilos Charles Steve
- Jay H. Knight
Industry Context
The medical device industry, particularly in areas like pain management and neurological disorders, is characterized by significant R&D investment, long product development cycles, and rigorous regulatory hurdles. Companies like electroCore face intense competition from both established players with broad product portfolios and innovative startups. Trends include a growing demand for non-invasive treatments and digital health integration.
Top Tags
filing (4) · 10-Q (4) · financials (4) · sec-filing (4) · management-change (3) · Medical Devices (2) · quarterly-report (2) · 10-K (2) · medical-devices (2) · financial-condition (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $10.931M | For the nine months ended September 30, 2025, widened from $8.658 million in 2024. |
| Net Sales | $22.789M | For the nine months ended September 30, 2025, up 25.6% from $18.136 million in 2024. |
| Cash Used in Operating Activities | $6.647M | For the nine months ended September 30, 2025, increased from $5.693 million in 2024. |
| Cash Position | $13.2M | Total cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2025. |
| Long-term Debt Issued | $7.5M | From Avenue Opportunities Fund II, L.P. during the nine months ended September 30, 2025. |
| Shelf Registration Statement | $100.0M | Aggregate amount remaining for potential issuance under the 2025 Shelf Registration Statement. |
| Selling, General and Administrative Expenses | $28.015M | For the nine months ended September 30, 2025, up from $22.881 million in 2024. |
| Common Stock Outstanding | 7,995,903 | Shares outstanding as of October 31, 2025. |
| Revenue for six months ended June 30, 2025 | $5.2M | Increased from $3.8M in 2024, a 36.8% growth. |
| Net loss for six months ended June 30, 2025 | $7.5M | Improved from $9.1M in 2024, a 17.5% reduction. |
| Revenue for quarter ended June 30, 2025 | $2.7M | Increased from $2.1M in 2024, a 28.6% growth. |
| Accumulated deficit as of June 30, 2025 | $278.9M | Indicates significant historical unprofitability. |
| Revenue growth for six months ended June 30, 2025 | 36.8% | Year-over-year increase in top-line performance. |
| Reduction in net loss for six months ended June 30, 2025 | 17.5% | Year-over-year improvement in profitability. |
| Grant Date Fair Value of Equity Awards for PEOs | $0 | Consistent across 2022, 2023, and 2024, indicating no new equity grants. |
Frequently Asked Questions
What are the latest SEC filings for Electrocore, Inc. (ECOR)?
Electrocore, Inc. has 27 recent SEC filings from Jan 2024 to Apr 2026, including 12 8-K, 6 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ECOR filings?
Across 27 filings, the sentiment breakdown is: 2 bearish, 23 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Electrocore, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Electrocore, Inc. (ECOR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Electrocore, Inc.?
Key financial highlights from Electrocore, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ECOR?
The investment thesis for ECOR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Electrocore, Inc.?
Key executives identified across Electrocore, Inc.'s filings include Dr. Peter J. McKenna, Ms. Karen L. King, Daniel S. Goldberger, Ira L. Kotel, Esq., Dr. Francis R. Smith and 3 others.
What are the main risk factors for Electrocore, Inc. stock?
Of ECOR's 24 assessed filings, 3 were flagged high-risk, 17 medium-risk, and 4 low-risk.
What are recent predictions and forward guidance from Electrocore, Inc.?
Forward guidance and predictions for Electrocore, Inc. are extracted from SEC filings as they are enriched.